Skip to Content
Merck
  • Differentiation by in vitro treatment of lidocaine-epinephrine and prilocaine-felypressine in neutrophils.

Differentiation by in vitro treatment of lidocaine-epinephrine and prilocaine-felypressine in neutrophils.

Immunology letters (2001-06-19)
Y Azuma, P L Wang, M Shinohara, K Ohura
ABSTRACT

Neutrophils are often the first cells of the immune system to encounter an invader, such as bacteria and fungi. Lidocaine-epinephrine induced transient potentiation of the production of superoxide anion, while prilocaine-felypressine induced persistent inhibition of the production in neutrophils. Moreover, lidocaine-epinephrine inhibited the production of hydrogen peroxide in spite that it potentiated the production of superoxide anion, while prilocaine-felypressine inhibited the production of hydrogen peroxide as well as superoxide anion. By contrast, lidocaine-epinephrine and prilocaine-felypressine are both effective in significantly inhibiting adhesion and phagocytosis. Using flow cytometric analysis, both local anesthetics were found to be effective in inhibiting the expression of Mac-1 (CD11b/CD18) in neutrophils. These results suggest that lidocaine-epinephrine and prilocaine-felypressine differentially modulate the production of superoxide anion, and could similarly inhibit adhesion, phagocytosis, and the production of hydrogen peroxide by neutrophils.

MATERIALS
Product Number
Brand
Product Description

Felypressin, European Pharmacopoeia (EP) Reference Standard